IMPEDIMED LIMITED (IPD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IPD - IMPEDIMED LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.07
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.092

12 Apr
2024

-0.001

OPEN

$0.09

-1.08%

HIGH

$0.09

289,598

LOW

$0.09

TARGET
$0.20 117.4% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
IPD: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A - 0.5 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-1.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx11.3 M
Book Value Per Share xxxxxxxxxxxxxxx3.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-18.0 M
Net Profit Margin xxxxxxxxxxxxxxx-180.90 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-36.67 %
Return on Invested Capital xxxxxxxxxxxxxxx-36.30 %
Return on Assets xxxxxxxxxxxxxxx-32.21 %
Return on Equity xxxxxxxxxxxxxxx-36.67 %
Return on Total Capital xxxxxxxxxxxxxxx-40.24 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-18.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx3 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx46 M
Price To Book Value xxxxxxxxxxxxxxx5.97

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx6.0 M
Capex % of Sales xxxxxxxxxxxxxxx53.27 %
Cost of Goods Sold xxxxxxxxxxxxxxx25 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx9 M
Research & Development xxxxxxxxxxxxxxx1 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

28/02/2024

1

Speculative Buy

$0.20

117.39%

ImpediMed's 1H results were in line with Morgans expectations. Revenue for the period was $4.8m, with 57 SOZO units sold (32 in the US), while total contracted value (TCV) signed in the 1H was $4m.

The Speculative Buy rating and 20c target are unchanged.

The broker notes new management will be focusing on high volume US states and cost control, a strategy the market will likely appreciate.

FORECAST
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -0.50 cents.
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.30 cents.

IPD STOCK CHART